NEW YORK (AdAge.com) -- Novartis has tapped Interpublic Group of Cos.' Deutsch, New York, for two direct-to-consumer drug accounts, executives close to the matter said.
The agency has won the Zelnorm account and the assignment for Diovan. The value of the accounts is not known.
Deutsch won the Zelnorm
Other contenders in the Diovan review were Grey Global Group's Grey Worldwide; Omnicom's Merkley Newman Harty; and Havas' Arnold Worldwide Partners. In the Diovan pitch, each agency partnered with shops that specialize in reaching health-care professionals.
A representative for Novartis did not immediately return a call for comment.
The two new accounts join Novartis' Lamisil assignment already at Deutsch.
Diovan treats hypertension, Zelnorm treats irritable bowel syndrome and Lamisil toenail fungus.
Hillary Chura and Rich Thomaselli contributed to this report.
CORRECTION: The original version of this story incorrectly reported that the Zelnorm account was worth $80 million. The value of the account cannot be confirmed.